Cutaneous Epithelioid/Pleomorphic Rhabdomyosarcoma, Melanoma in Disguise? An Immunohistochemical, Molecular, and Epigenetic Study of 13 Patients
Modern Pathology · 2026
DOI: 10.1016/j.modpat.2026.100983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2026. Verfasst von Veronica Ulici und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Cleveland Clinic, Cleveland, Ohio. Hauptthemen laut MEDLINE: Skin Neoplasms, Melanoma, Rhabdomyosarcoma, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, Cleveland Clinic, National Cancer Institute.
Abstract (Originalsprache)
Rhabdomyosarcomatous transdifferentiation is a rare but well-documented phenomenon in melanoma, and, in these cases, recognition of a conventional component by either morphology or immunophenotype is essential for the correct diagnosis. However, tumors that are entirely transdifferentiated can be impossible to distinguish from primary rhabdomyosarcoma. We analyzed a cohort of cases diagnosed as cutaneous epithelioid/pleomorphic rhabdomyosarcoma using genetic/epigenetic techniques and compared them with melanoma. Cases diagnosed as cutaneous epithelioid/pleomorphic rhabdomyosarcoma were retrieved, and clinicopathologic features were documented. NRAS p.Q61R and BRAF p.V600E immunohistochemistry, targeted DNA next-generation sequencing, and DNA methylation profiling were performed. A total of 13 cases of cutaneous epithelioid/pleomorphic rhabdomyosarcomas were identified in 10 males and 3 females (62-90 years; median, 83 years). Cases included tumors arising in the head and neck (n = 9), upper extremity (n = 2), lower extremity (n = 1), and back (n = 1). Using immunohistochemistry, 1 tumor (of 13) was positive for NRAS Q61R; all were negative for BRAF V600E expression (0/13). Targeted DNA next-generation sequencing revealed 1 case each to harbor HRAS c.34G>A p.G12S and BRAF c.1363G>A p.G455R mutations, respectively. Tumor mutation burden was interpretable in 5 cases and ranged from 3 to 80 Mut/Mb (median 38 Mut/Mb); 4 of 5 cases had tumor mutation burden > 10 Mut/Mb. A DNA UV light mutational signature was present in all cases with evaluable data (6/6). DNA methylation profiling showed 7 (of 9) cases to cluster with desmoplastic melanoma, whereas 1 case formed a partial match for head and neck squamous cell carcinoma, and the final case matched with TFCP2-rearranged rhabdomyosarcoma. At the last follow-up, 4 patients died from the disease, 2 died from unknown causes, 2 were alive without disease, and 1 was alive with disease. The majority of cutaneous epithelioid/pleomorphic rhabdomyosarcoma show clinical, genetic, and epigenetic profiles similar to melanoma, suggesting that a major subset represents transdifferentiated melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Cleveland Clinic, Cleveland, Ohio.
- Bone Tumor Reference Center at the Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Pennsylvania.
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Basel Research Centre for Child Health, Basel, Switzerland.
- Department of Pathology, Cleveland Clinic, Cleveland, Ohio. Electronic address: billins@ccf.org.
Förderung
- NIH HHS
- Cleveland Clinic
- National Cancer Institute
- Gertrude von Meissner-Stiftung
- National Institutes of Health
Zitieren
APA
Ulici, V., Ameline, B., John, I., Dermawan, J. K., Karunamurthy, A., Dehner, C. A., Fernandez, A. P., Azzato, E., Hattery, T., Kilpatrick, S. E., Isaacson, A. L., Ko, J. S., Fritchie, K. J., Baumhoer, D., & Billings, S. D. (2026). Cutaneous Epithelioid/Pleomorphic Rhabdomyosarcoma, Melanoma in Disguise? An Immunohistochemical, Molecular, and Epigenetic Study of 13 Patients. Modern Pathology. https://doi.org/10.1016/j.modpat.2026.100983
Vancouver
Ulici V, Ameline B, John I, Dermawan JK, Karunamurthy A, Dehner CA, et al. Cutaneous Epithelioid/Pleomorphic Rhabdomyosarcoma, Melanoma in Disguise? An Immunohistochemical, Molecular, and Epigenetic Study of 13 Patients. Modern Pathology. 2026. doi:10.1016/j.modpat.2026.100983
BibTeX
@article{Ulici2026,
author = {Ulici, Veronica and Ameline, Baptiste and John, Ivy and Dermawan, Josephine K and Karunamurthy, Arivarasan and Dehner, Carina A and Fernandez, Anthony P and Azzato, Elizabeth and Hattery, Travis and Kilpatrick, Scott E and Isaacson, Alexandra L and Ko, Jennifer S and Fritchie, Karen J and Baumhoer, Daniel and Billings, Steven D},
title = {Cutaneous Epithelioid/Pleomorphic Rhabdomyosarcoma, Melanoma in Disguise? An Immunohistochemical, Molecular, and Epigenetic Study of 13 Patients},
journal = {Modern Pathology},
year = {2026},
doi = {10.1016/j.modpat.2026.100983}
}
EUVIMED